New York?John L. Phillips, MD, is the new physician-in-charge of urologic oncology at Beth Israel Medical Center, New York.
Neoadjuvant chemotherapy found safe, efficacious in penile cancer
Those who experienced a response with neoadjuvant chemotherapy had a median overall survival of 73.0 months, compared with 17.0 months among non-responders.
Dr. Schwen on focal therapies for prostate cancer
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Initial results published for 177Lu-rhPSMA-10.1 in mCRPC
All patients treated with 177Lu-rhPSMA-10.1 had reductions in their PSA levels from the start of treatment and none experienced a serious treatment-related adverse event.
Speaking of Urology: Liquid biopsy in prostate cancer
In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.
AUGS Position Statement: Vaginal Pessary Use and Management for Pelvic Organ Prolapse
The purpose of this clinical consensus statement is to identify areas of expert consensus and nonconsensus regarding pessary fitting, follow-up, and management of pessary complications to improve the safety and quality of care where evidence is currently limited.
OS benefit with darolutamide maintained throughout mHSPC treatment course
"Post-hoc sensitivity analyses from the phase 3 ARASENS trial presented at ASCO GU were consistent with and supportive of the ARASENS primary OS analysis–reinforcing darolutamide plus ADT plus docetaxel as an effective and well tolerated standard of care in patients with mHSPC," writes Neal Shore, MD, FACS.
2 Commerce Drive Cranbury, NJ 08512